Aceragen, Inc. to Delist from The Nasdaq Stock Market
2023年8月5日 - 5:30AM
Aceragen, Inc. (the “Company”) (Nasdaq: ACGN), announced today that
the Company intends to voluntarily terminate the listing of its
common stock on the Nasdaq Capital Market (“Nasdaq”) by filing a
Form 25 with the Securities and Exchange Commission (the “SEC”) on
or about August 15, 2023. As previously disclosed, on August 14,
2023, the Company expects to hold a special meeting seeking
stockholder approval to effect a transfer and assignment of
substantially all of the Company’s assets to an assignee for the
benefit of creditors (the “Assignment Proposal”). Subject to
stockholder approval of the Assignment Proposal, and in order to
ensure an orderly delisting process, the Company has determined to
voluntarily terminate the listing of its common stock on the Nasdaq
by filing a Form 25 with the SEC on or about August 15, 2023.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements, other than statements of historical fact, included
or incorporated in this press release, including, without
limitation, statements regarding the Company’s intention to file a
Form 25 with the SEC, are forward-looking statements. The words
“believes,” “anticipates,” “estimates,” “plans,” “expects,”
“intends,” “may,” “could,” “should,” “potential,” “likely,”
“projects,” “continue,” “will,” “schedule,” and “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are predictions
based on our current expectations and projections about future
events and various assumptions. We cannot guarantee that we will
achieve the plans, intentions, or expectations disclosed in our
forward-looking statements and you should not place undue reliance
on our forward-looking statements. These forward-looking statements
involve known and unknown risks, uncertainties, and other factors,
which may be beyond our control. All forward-looking statements
included in this press release are made as of the date hereof and
are expressly qualified in their entirety by this cautionary
notice, including, without limitation, those risks and
uncertainties described in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2022, and otherwise in the
Company’s subsequent filings and reports filed with the SEC. The
Company does not assume any obligation to update any
forward-looking statements and it disclaims any intention or
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events, or
otherwise, except as may be required by law.
Contact:Aceragen, Inc.John
Taylor Jtaylor@aceragen.com
Aceragen (NASDAQ:ACGN)
過去 株価チャート
から 4 2024 まで 5 2024
Aceragen (NASDAQ:ACGN)
過去 株価チャート
から 5 2023 まで 5 2024